Paper 105 - EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: RESULTS FROM THE MOTION PHASE 3 TRIAL

Author(s)

• NB

  Nicholas M. Bernthal, MD

  University of California Los Angeles
  Los Angeles, California, United States

  Slides

Co-Author(s)

• WT

  William D. Tap, MD

  Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College
  New York, New York, United States
• 

  Vivek A. Bhadri, MD, PhD

  Medical Oncologist
  Chris O’Brien Lifehouse
  Camperdown, New South Wales, Australia
• SS

  Silvia Stacchiotti, MD

  Medical Oncologist
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Lombardia, Italy
• SB

  Sebastian Bauer, MD (he/him/his)

  Director
  Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, and German Cancer Consortium (DKTK), Partner Site University Hospital Essen
  Essen, Nordrhein-Westfalen, Germany
• AW

  Andrew J. Wagner, MD, PhD

  MD, PhD
  Dana-Farber Cancer Institute
  Boston, Massachusetts, United States
• 

  Michiel AJ van de Sande, Professor (he/him/his)

  Professor in Orthopedic Oncology
  Princes Maxima Center for pediatric oncology and LUMC leiden
  Utrecht / Leiden, Zuid-Holland, Netherlands
• AL

  Antonio López Pousa, MD

  Hospital de la Santa Creu i Sant Pau
  Barcelona, Catalonia, Spain
• AA

  Albiruni Abdul Razak, MB BCh, BAO, LRCP & SI

  Toronto Sarcoma Program, Princess Margaret Cancer Center
  Toronto, Ontario, Canada
• AI

  Antoine Italiano, MD, PhD

  Institut Bergonié
  Bordeaux, Aquitaine, France
• MA

  Mahbubl Ahmed, MSc, MBBS, PhD

  University College London Hospitals NHS Foundation Trust
  London, England, United Kingdom
• AL

  Axel Le Cesne, MD

  Gustave Roussy
  Villejuif, Rhone-Alpes, France
• CT

  Christopher Tait, PhD

  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• AS

  Amanda Saunders, DO

  Deciphera Pharmaceuticals, LLC
  waltham, Massachusetts, United States
• BH

  Brooke Harrow, PhD

  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• MS

  Maitreyi G. Sharma, MD

  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• RR

  Rodrigo Ruiz-Soto, MD

  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• MS

  Matthew L. Sherman, MD

  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• JB

  Jean-Yves Blay, MD, PhD

  Centre Léon Bérard
  Lyon, Rhone-Alpes, France
• HG

  Hans Gelderblom, MD, PhD

  Leiden University Medical Center
  Leiden, Zuid-Holland, Netherlands